Synthetic bottom-up approach reveals the complex interplay of Shigella effectors in regulation of epithelial cell death

Xiangyu Mou\textsuperscript{a,b,c}, Skye Souter\textsuperscript{a,b}, Juan Du\textsuperscript{a,b,d,e}, Analise Z. Reeves\textsuperscript{a,b}, and Cammie F. Lesser\textsuperscript{a,b,c,1}

\textsuperscript{a}Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, MA 02139; \textsuperscript{b}Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115; \textsuperscript{c}Broad Institute of MIT and Harvard, Cambridge, MA 02142; \textsuperscript{d}Centre for Translational Microbiome Research, Karolinska Institutet; \textsuperscript{e}Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177, Sweden

Edited by Daniel A. Portnoy, University of California, Berkeley, CA, and approved May 9, 2018 (received for review January 23, 2018)

Over the course of an infection, many Gram-negative bacterial pathogens use complex nanomachines to directly inject tens to hundreds of proteins (effectors) into the cytosol of infected host cells. These effectors rewire processes to promote bacterial replication and spread. The roles of effectors in pathogenesis have traditionally been investigated by screening for phenotypes associated with their absence, a top-down approach that can be limited, as effectors often act in a functionally redundant or additive manner. Here we describe a synthetic Escherichia coli-based bottom-up platform to conduct gain-of-function screens for roles of individual Shigella effectors in pathogenesis. As proof of concept, we screened for Shigella effectors that limit cell death induced on cytotoxic entry of bacteria into epithelial cells. Using this platform, in addition to OspC3, an effector known to inhibit cell death via pyroptosis, we have identified OspD2 and IpaH1.4 as cell death inhibitors. In contrast to almost all type III effectors, OspD2 does not target a host cell process, but rather regulates the activity of the Shigella type III secretion apparatus limiting the cytosolic delivery (translocation) of effectors during an infection. Remarkably, by limiting the translocation of a single effector, VirA, OspD2 controls the timing of epithelial cell death via calpain-mediated necrosis. Together, these studies provide insight into the intricate manner by which Shigella effectors interact to establish a productive intracytoplasmic replication niche before the death of infected epithelial cells.

type III secretion system | innate immunity | T3SS | pyroptosis | necrosis

Induced cell death is a major arm of the host innate immune response activated in response to recognition of invading bacterial pathogens. While the majority of studies in this area have focused on macrophages, infected epithelial cells, particularly those lining mucosal surfaces, behave similarly (1). Cell death results in the eradication of the niche that intracellular pathogens use for replication, as well as the release of alarmers and proinflammatory cytokines that recruit additional immune cells to sites of infection (2). In response, bacterial pathogens, particularly those that invade host cells, have evolved intricate means to manipulate cell death pathways to their own advantage (3): for example, Shigella species, professional intracytoplasmic pathogens, actively trigger cell death of macrophages while suppressing cytotoxicity of infected intestinal epithelial cells.

The causative agents of bacillary dysentery, Shigella are transmitted via a fecal-oral route. On reaching the colon, Shigella traverse the intestinal mucosa through microfold (M) cells after which they are engulfed by underlying resident macrophages. Once internalized, Shigella trigger rapid macrophage cell death via pyroptosis, primarily due to activation of canonical inflammasomes (4). This results in the release of viable Shigella at the basolateral surface of epithelial cells, which they preferentially invade. Within epithelial cells, Shigella inhibit cell death via both pyroptosis (5) and necrosis (6) to establish a replicative niche within the colonic epithelium.

The pathogenesis of Shigella, like many other Gram-negative bacteria, is dependent on a type III secretion system (T3SS), a syringe-like nanomachine that serves as a conduit to transfer proteins (effectors) directly from bacteria into the cytosol of targeted host cells (7). In addition to components of the translocon, the portion that forms a pore in the host cell membrane, T3SSs translocate tens to hundreds of effectors into host cells. In the case of Shigella, at least 30 secreted effectors have been identified, the majority of which are encoded on a large virulence plasmid (8, 9). The roles of effectors from Shigella and other pathogens have been traditionally studied via top-down approaches focused on screening for loss-of-function phenotypes associated with strains that no longer encode one or more effectors. However, this approach is limited when studying effectors that work in a functionally redundant or additive manner, a not too uncommon occurrence. For example, in the case of Shigella, one set of at least five effectors coordinates uptake into epithelial cells (10–13), while another comparably sized set inhibits the production of proinflammatory cytokines by blocking NF-κB activation (14–22).

Here we describe the development of a complementary bottom-up platform to conduct gain-of-function screens to identify roles of individual Shigella effectors in pathogenesis. This approach is an extension of a recombineering-based synthetic biology platform that we previously developed to introduce variants of the Shigella T3SS into laboratory strains of Escherichia coli (23, 24). The newest strain described herein, mT3.1\textsubscript{E. coli}, not only invades epithelial cells.

Significance

The virulence of numerous bacterial pathogens is dependent on nanomachines that inject tens of proteins (effectors) into host cells. Effectors are often functionally redundant or act in an additive manner to usurp cellular processes, limiting their characterization via traditional top-down loss-of-function assays. To overcome this issue, we developed an innovative synthetic bottom-up platform to conduct gain-of-function screens. These screens identified previously missed Shigella effectors that inhibit induced epithelial cell death, an important arm of the host innate immune system triggered in response to invading pathogens. Our studies provide new mechanistic insight into the sophisticated strategies by which Shigella effectors interact with the host to enable this pathogen to establish a replicative niche within the cytosol of infected epithelial cells.

Author contributions: X.M. and C.F.L. designed research; X.M., S.S., J.D., and A.Z.R. performed research; X.M. and C.F.L. analyzed data; and X.M. and C.F.L. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

Published under the PNAS license.

\textsuperscript{1}To whom correspondence should be addressed. Email: clesser@mgh.harvard.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1803131115/-/DCSupplemental.

Published online June 4, 2018.
cells at levels equivalent to wild-type (WT) Shigella, but also recognizes “added-back” Shigella effectors as secreted proteins. Using this platform, we find that the introduction of OspC3, IpaH1.4, or OspD2 into mT3.1 E. coli suppresses bacterial-triggered epithelial cell death. Notably, the absence of either of the latter two effectors was not observed to trigger excess cell death in a previous reciprocal top-down screen (5). Our follow-up studies demonstrate that in contrast to almost all characterized effectors, OspD2 does not target a host cell process, but rather regulates the activity of the Shigella type III secretion apparatus (T3SA), limiting effector translocation into host cells. Furthermore, we determined that OspD2 regulates Shigella-triggered cell death, not by inhibiting the delivery of bacterial PAMPS (pathogen-associated molecular patterns), but rather by restricting the translocation of another effector, VirA, into host cells, thus limiting cell death via calpain-mediated necrosis. These results highlight the complex means by which Shigella effectors interact to establish a replicative niche within the cytosol of infected epithelial cells.

Results

A Synthetic Bottom-Up Platform to Study Shigella Type III Secreted Effectors. We recently developed a recombineering approach that we used to transfer a 31-kb region of the large Shigella virulence plasmid (VP) onto a smaller autonomously replicating plasmid (23, 24). The introduction into DH10 β E. coli of this plasmid, which encodes all of the structural components of the Shigella T3SA plus a few embedded effectors, plus a second that carries VirB, a major T3SS transcriptional regulator, resulted in the generation of mT3 E. coli. Like WT Shigella, mT3 E. coli invade and enter the cytosol of epithelial cells (HeLa), albeit with lower efficiency (24).

Here we extended the region of VP DNA introduced into DH10 β E. coli to include two additional small, poorly characterized genes, orf131a and orf131b (Fig. 1A). This modification led to the development of mT3.1 E. coli, a strain that displays increased T3SA activity. In contrast to mT E. coli, mT3.1 E. coli secretes compo-nors VirA, a translocon (IpaB, IpaC, and IpaD) at levels equivalent to both WT Shigella and VP E. coli. DH10 β E. coli that carry the Shigella VP (Fig. 1 B and C). In addition, mT3.1 E. coli invade a similar percentage of HeLa cells as WT Shigella and VP E. coli, as assessed using an inside/outside fluorescent microscopy assay that differentiates between internalized and extracellular bacteria (Fig. 1 D and E).

We next investigated the breadth of Shigella effectors recognized as secreted proteins by mT3.1 E. coli. To directly compare levels of secreted effectors, we studied the behavior of FLAG-tagged variants. Furthermore, to avoid issues with the expression of effectors, which in Shigella are expressed and secreted in two waves (25), we studied effector variants expressed under the control of an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible promoter. As shown in Fig. 1F, each effector tested was recognized as a secreted protein and, notably, found in the supernatant fractions at similar relative levels as previously observed when the same effector constructs were studied in WT Shigella (26). These observations suggested that mT3.1 E. coli could serve as a bottom-up platform to study Shigella effectors.

Activation of Noncanonical Inflammasomes by mT3.1 E. coli Is Suppressed by the Addition of OspD2, IpaH1.4, or OspC3. Given our prior observations that mT3 E. coli not only invade, but also escape into the cytosol of infected epithelial cells (24), we hypothesized that mT3.1 E. coli might serve to identify effectors involved in post-entry steps of Shigella pathogenesis, including induced host cell death. To investigate this possibility, we compared the levels of cytotoxicity of epithelial cells infected with mT3.1 E. coli, WT Shigella, and VP E. coli. To distinguish between live and dead cells, we used a fluorescent microscopy assay, in which all cell nuclei were visualized with Hoechst, but only those with a compromised plasma membrane with propidium iodide (PI) (21). As shown in Fig. 2 A and B, HeLa cells infected with mT3.1 E. coli exhibited substantially more cytotoxicity than those infected with WT Shigella or VP E. coli (15% vs. 4% vs. 4%), suggesting that
mT3.1_E. coli trigger greater cytotoxicity due to differences in effector content rather than to inherent differences between Shigella and DH10β E. coli.

We proceeded to screen for VP-encoded effectors that suppress mT3.1_E. coli triggered epithelial cell death. To increase the detection window for this screen, before adding gentamicin to kill extracellular bacteria, we infected epithelial cells for 60 min instead of 30 min, a change that resulted in a doubling of the percentages of both infected cells and dying cells (SI Appendix, Fig. S1). Our subsequent high-throughput and confirmatory screens identified three effectors—OspC3, IpaH1.4, and OspD2—that inhibited mT3.1_E. coli-triggered epithelial cell death (Fig. 2C and SI Appendix, Fig. S2). Of note, in a prior top-down-screen, OspC3 was the sole effector identified to suppress epithelial cell death (5). Our observation that the addition of OspC3 suppresses cell death provided a proof of concept for our approach. In addition, the prior determination that OspC3 prevents Shigella triggered cell death via pyroptosis due to activation of noncanonical inflammasomes (5) suggested that mT3.1_E. coli trigger cell death via this pathway. Indeed, as shown in Fig. 2D, HeLa cells infected with mT3.1_E. coli but not OspC3-expressing mT3.1_E. coli secrete elevated levels of IL-18, a proinflammatory cytokine released by pyroptotic epithelial cells.

OspD2 Inhibits mT3.1_E. coli Host Cell Invasion by Inhibiting Activity of the Shigella T3SA. We next focused our efforts on dissecting the role of OspD2, an effector about which essentially nothing was previously known, in regulating bacteria-triggered cell death. We first investigated whether OspD2 plays a role in mT3.1_E. coli host cell invasion. Using the inside/outside microscopy assay, we found that OspD2-expressing mT3.1_E. coli invade approximately 50% fewer HeLa cells than those expressing OspC3 or IpaH1.4 (Fig. 2E). The degree to which OspD2 blocks invasion was essentially equivalent to the degree to which it suppresses cell death. Thus, we hypothesized that OspD2 directly blocks either the translocation or the activity of mT3.1_E. coli effectors that promote host cell invasion. The former turned out to be true, as we observed that expression of OspD2 inhibits the secretion of IpaB, IpaC, and IpaD, the three secreted components of the translocon, in infected cells. As well as the two natively expressed effectors tested, OspE and VirA, but not the unrelated type V secreted protein, SepA (Fig. 3A). Consistent with this secretion inhibition, as observed with mT3.1_E. coli, IPTG-induced expression of OspD2 before contact with host cells inhibited epithelial cell invasion (SI Appendix, Fig. S3A). However, strains lacking OspD2 (ΔospD2 Shigella) secreted equivalent levels of IpaB, IpaC, IpaD, OspF, and VirA as WT Shigella (Fig. 3B), and ΔospD2 and WT Shigella invaded equivalent percentages of HeLa cells (SI Appendix, Fig. S3B). These seemingly conflicting observations suggested that, although OspD2 inhibits secretion, it does not inhibit host cell invasion. To test this hypothesis, we infected epithelial cells infected with ΔospD2 Shigella (Fig. 3C). These observations suggest that secretion inhibition is OspD2-specific.

OspD2 Regulates the Levels of Proteins Translocated into the Cytosol of Infected Cells. We next investigated whether OspD2 regulates the levels of proteins translocated into the cytosol of infected cells. We first investigated whether OspD2 regulates the levels of proteins translocated into the cytosol of infected cells. To increase the detection window for this screen, before adding gentamicin to kill extracellular bacteria, we infected epithelial cells for 60 min instead of 30 min, a change that resulted in a doubling of the percentages of both infected cells and dying cells (SI Appendix, Fig. S1). Our subsequent high-throughput and confirmatory screens identified three effectors—OspC3, IpaH1.4, and OspD2—that inhibited mT3.1_E. coli-triggered epithelial cell death (Fig. 2C and SI Appendix, Fig. S2). Of note, in a prior top-down-screen, OspC3 was the sole effector identified to suppress epithelial cell death (5). Our observation that the addition of OspC3 suppresses cell death provided a proof of concept for our approach. In addition, the prior determination that OspC3 prevents Shigella triggered cell death via pyroptosis due to activation of noncanonical inflammasomes (5) suggested that mT3.1_E. coli trigger cell death via this pathway. Indeed, as shown in Fig. 2D, HeLa cells infected with mT3.1_E. coli but not OspC3-expressing mT3.1_E. coli secrete elevated levels of IL-18, a proinflammatory cytokine released by pyroptotic epithelial cells.
expressing (untagged) OspD2 via its native promoter (Fig. 3E) or OspD2-FLAG via an IPTG-regulated promoter (SI Appendix, Fig. S4), the latter further supporting a role for OspD2 in the regulation of postinvasion T3SA activity. Notably, the levels of IpaB, IpaC, IpaD, OspF, and VirA present in the insoluble pellet fractions of WT and ΔospD Shigella infected cells, which contain intact bacteria, were similar, suggesting that OspD2 is not a transcriptional regulator, but rather directly controls the secretory activity of the T3SA.

**OspD2 Regulates Timing of Epithelial Cell Death.** We next investigated whether, as in the context of mT3.1 E. coli, OspD2 modulates Shigella-triggered epithelial cell death. By 6 hpi, cells infected with ΔospD2 Shigella exhibited significantly more cytotoxicity than those infected with WT Shigella, a phenotype fully complemented by endogenously expressed (untagged) OspD2 (Fig. 4A). We also examined the consequences of overexpression of OspD2 postinvasion of host cells by inducing its expression with IPTG along with gentamicin, thus restricting OspD2 expression to live intracellular Shigella. When assayed at 8 h postinvasion, excess OspD2 expression markedly inhibits epithelial cell death (SI Appendix, Fig. S5A).

Interestingly, under the same infection conditions, we observed similar levels of cytotoxicity of epithelial cells infected with ΔospC3 (Fig. 4B) and ΔospD2 Shigella, yet only cells infected with ΔospC3 released IL-18, a reporter of cell death via pyroptosis (Fig. 4C). Similarly, the addition of the pan-caspase inhibitor, Z-VAD-FMK, which inhibits cell death via both pyroptosis and apoptosis, suppressed ΔospC3 but not ΔospD2 Shigella triggered HeLa cell death (Fig. 4D). Together these observations suggested that OspD2 does not inhibit cell death via either pyroptosis or apoptosis.

OspD2 shares extensive homology (29% identity and 66% similarity) with EspL, an enteropathogenic E. coli (EPEC) type III effector (SI Appendix, Fig. S5B). EspL is a cysteine protease that limits EPEC-triggered epithelial cell death by targeting host cell proteins for degradation (29). To test whether OspD2 is also a cysteine protease, we generated OspD2_C79A, an OspD2 variant engineered to carry a mutation that would render it catalytically dead if it were a cysteine protease. Overexpression of OspD2 and OspD2_C79A postinvasion similarly reduce cell death (SI Appendix, Fig. S5A). Thus, it is highly unlikely that OspD2 is a cysteine protease that targets degradation of mammalian or bacterial proteins.

**OspD2 Limits VirA-Triggered Calpain-Mediated Cell Death.** Based on the lytic appearance of the PI-stained epithelial cells infected with ΔospD2 and WT Shigella, we next investigated whether OspD2 delays epithelial cell death by limiting VirA-mediated necrosis (30). VirA, a type III secreted effector, is involved in multiple steps of Shigella pathogenesis. Initially, VirA works in concert with other effectors to mediate epithelial invasion and cell-to-cell spread. Later, after establishment of an infection, VirA-mediated calpain activation triggers epithelial cell death via necrosis (30).

Under our experimental infection conditions, starting as early as 6 hpi, as reported previously, we observed that ΔvirA Shigella triggers substantially less cell death than WT Shigella (Fig. 5A). This phenotype is not due to decreased invasion or spread, as under these same infection conditions, we isolated equivalent numbers of ΔvirA and WT Shigella from infected HeLa cells at 2, 4, and 6 hpi (SI Appendix, Fig. S6).

Next, to directly test whether OspD2 regulates epithelial cell death by limiting VirA translocation (Fig. 3E), we monitored levels of epithelial cell death triggered in response to WT, ΔvirA, ΔospD2, and ΔvirAΔospD2 Shigella. At 8 hpi, epithelial cells infected with the single deletion strains behaved as expected, with increased cytotoxicity observed with ΔospD2 and decreased cytotoxicity observed with ΔvirA Shigella. Remarkably, cells infected with ΔvirAΔospD2 Shigella exhibited levels of cytotoxicity essentially identical to those of cells infected with ΔvirA Shigella (Fig. 5B), suggesting the excess cell death observed in the absence of OspD2 is directly attributable to VirA translocation.
translocation into epithelial cells, OspD2 regulates the extent and timing of epithelial cell death via calpain-mediated necrosis.

**Discussion**

Induced inflammatory death of intestinal epithelial cells is emerging as a major arm of the host innate immune response activated in response to invading intestinal pathogens, including *Shigella* species. In response, *Shigella*, professional intracytoplasmic pathogens, have evolved intricate means of modulating host cell death signaling pathways to establish a productive replicative niche within the cytosol of intestinal epithelial cells. Here we describe the development of an innovative synthetic bottom-up platform to interrogate roles for *Shigella* effectors in specific steps in pathogenesis that circumvents issues with functional redundancy. Using this bottom-up platform, we have identified three effectors—OspC3, OspD2, and IpaH1.4—that suppress *Shigella*-triggered epithelial cell death, the latter two of which were previously missed by a reciprocal traditional top-down loss-of-function screen, thus demonstrating the strength of this platform. Our follow-up studies with OspD2 establish that it regulates the timing of epithelial cell death by modulating the activity of the *Shigella* T3SSA, limiting the translocation of effectors into host cells during an infection.

OspD2 is the third effector from a bacterial pathogen that has been demonstrated to regulate translocation activity, the other two being *Yersinia* YopK and EPEC/EHEC EspZ (31, 32). After being translocated into host cells, YopK and EspZ likely block translocation through interactions with the translocon (31, 33). In contrast, our data suggest that OspD2 inhibits T3SSA activity from within *Shigella*, as we observe inhibition of effector secretion into the media as well as translocation into host cells. Notably, unlike its homolog OspD1, a type III effector involved in regulating the activity of the transcription of second-wave *Shigella* effectors (34), we observe no evidence of similar activity for OspD2. One intriguing possibility is that OspD2 is an impassable substrate that over time accumulates and clogs the secretion apparatus. However, as shown in Fig. 1F, low levels of OspD2 are secreted into the media and, in previous studies, translocated into host cells (35), at least when under the control of an IPTG-regulated promoter. Additional studies are needed to assess the molecular mechanism by which OspD2 regulates T3SSA activity.

**Why would *Shigella* want to limit the translocation of effectors into epithelial cells?** Our data demonstrate that by limiting VirA translocation, OspD2 delays calpain-mediated cell death via necrosis, thus enabling intracytoplasmic *Shigella* to replicate to higher titers before epithelial cell death occurs. Of note, however, our observations suggest that OspD2 acts to globally inhibit effector translocation. Might limiting the translocation of other effectors, such as those involved in inhibiting the production of proinflammatory cytokines or cell death via pyroptosis, have detrimental effects on *Shigella* survival? Interestingly, once inside epithelial cells, *Shigella* modify LPS, converting it to hypoacylated state associated with reduced NF-kB and inflammasome activation (36), likely negating the need for effectors that inhibit...
these pathways at later time points. Thus, at this point the strategy likely turns to one of preserving the Shigella’s intracytoplasmic niche within the intestinal epithelium such that at a later point, when the massive inflammatory infiltration, tissue destruction, and a profuse inflammatory diarrhea associated with Shigella infection have developed, the intracytoplasmic Shigella escape at high titers from dying epithelial cells into the intestinal lumen and spread to new hosts via a fecal-oral route.

Materials and Methods

Cell lines. HE-la cells (American Type Culture Collection; CCL2) were cultured as recommended in a 5% CO2 incubator at 37 °C. Bacterial strains, plasmids, and primers are summarized in SI Appendix, Tables S1–S3. Strain construction, growth, and infection conditions are described in SI Appendix, Materials and Methods.

Inside/Outside Microscopy. As described previously (24), HE-la cells on coverslips were infected at a multiplicity of infection (MOI) of 100. At 1 h after the start of an infection, the coverslips were washed five times with PBS and then fixed with paraformaldehyde. Extracellular bacteria were labeled with rabbit anti-E. coli or anti-Shigella polyclonal antibodies, followed by labeling with anti-rabbit Alexa Fluor 488 secondary antibody. Cells were then permeabilized with 0.5% Triton X-100 and stained with DAPI. Bacteria labeled with blue, but not green, were defined as intracellular, and those labeled with both were defined as extracellular. Hela cells containing intracellular bacteria were defined as infected. Additional details are provided in SI Appendix, Materials and Methods.

Cytotoxicity Assay. HE-la cells were infected at an MOI of 100. At designated time points, cells were incubated with Hoechst and PI for 30 min before imaging. Stained cell nuclei were identified and quantified using CellProfiler 2.0 (37). Cell nuclei labeled with only blue were defined as live, and those labeled with both blue and red were defined as dead. Additional details are provided in SI Appendix, Materials and Methods.

Translocation Assays. As reported previously (38), HE-la cells were infected at an MOI of 30 for 60 min before the addition of gentamicin to the media. At designated time points, cells were incubated in ice cold radioimmunoprecipitation assay (RIPA) buffer to lyse mammalian cells, but not bacterial cells. The pellet fraction, containing intact bacteria, was resuspended in Laemmli sample buffer while the supernatant was centrifuged a second time, and the resulting supernatant was designated the soluble fraction. Additional details are provided in SI Appendix, Materials and Methods.

Detailed information on all other methods, including secretion assays, quantification of secreted IL-18, gentamicin protection assays, alignment of protein sequences, and statistical analysis, are available in SI Appendix, Materials and Methods.

ACKNOWLEDGMENTS. We thank W. Spears, W. Polacheck, and N. Ernst for helping with plasmid construction; L. Knodler, J. Coers, C. Gonzalez-Prieto, L. Goers, and J. Lynch for critically reading the manuscript; W. L. Picking, A. T. Maurelli, and M. B. Goldberg for sharing reagents/strains; and J. Boyd for assisting with high-content microscopy. This work was supported by National Institutes of Health Grant R01 AI064285 and a Brit d’Aberleoff Research Scholar award (to F.C.L.).